Mesothelioma Center at Loyola Will Grow Under VigneswaranTreatment & Doctors
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Povtak, T. (2020, October 16). Mesothelioma Center at Loyola Will Grow Under Vigneswaran. Asbestos.com. Retrieved October 7, 2022, from https://www.asbestos.com/news/2016/01/18/mesothelioma-center-loyola-wickii-vigneswaran/
Povtak, Tim. "Mesothelioma Center at Loyola Will Grow Under Vigneswaran." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/news/2016/01/18/mesothelioma-center-loyola-wickii-vigneswaran/.
Povtak, Tim. "Mesothelioma Center at Loyola Will Grow Under Vigneswaran." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/news/2016/01/18/mesothelioma-center-loyola-wickii-vigneswaran/.
Renowned thoracic surgeon Dr. Wickii Vigneswaran left the Loyola University Health System 10 years ago to help start the lung transplant program at nearby University of Chicago Medical Center.
He returned to Loyola this year to direct a mesothelioma specialty center, bringing his decade of experience from one of the country’s finest research facilities.
“I’ve got the best of both worlds now, and I think patients will really benefit from that,” Vigneswaran told Asbestos.com. “We’ll continue to collaborate with the best researchers, but now I’ll have a broader clinical base at Loyola. It’s a win-win situation for everyone.”
Vigneswaran performed more than 200 surgeries for mesothelioma patients, along with the lung transplants, during his 10 years at the Chicago Medical Center. He did the aggressive extrapleural pneumonectomy (EPP) and the lung sparing but more detailed pleurectomy/decortication (P/D) surgeries. He earned his reputation there as one of America’s finest mesothelioma specialists.
He returned to the Loyola School of Medicine as professor and chief of thoracic and cardiovascular surgery, starting the new year at his old place of employment.
“My goal now is to build a really robust [mesothelioma] program at Loyola, both clinically and academically. I’m really excited about coming back and utilizing the great resources we have here,” he said. “When you make a move like this, it allows you to think outside the box a little more, bring fresh new ideas, which is what we need to keep making progress with mesothelioma treatment.”
Pioneering Advances in Mesothelioma Treatment
With more than two decades of surgery experience, Vigneswaran has been part of several, much-chronicled studies in recent years. He is a national leader in the growing belief that age should not be a deterrent to aggressive, possibly curative surgery for mesothelioma.
Through his surgeries at UC, he discovered that advanced age of patients did not translate into higher mortality rates or shorter long-term survival periods, dispelling a myth that had dominated the way patients were handled previously.
He was part of the first study that measured how P/D surgery decreased pulmonary function with early-stage mesothelioma but preserved pulmonary function and improved quality of life for mesothelioma patients with advanced disease.
In joining the Loyola Health System, he will be part of the Cardinal Bernardin Cancer Center, which is nationally recognized for its multidisciplinary approach and collaboration between health care providers.
Broader Clinical Reach for Mesothelioma at Loyola
The Loyola Medical Center is just a part of the main health center campus that includes the Stritch School of Medicine, the Loyola outpatient clinic, the cancer center and a 250-bed hospital.
Vigneswaran also will be involved at the nearby Loyola-affiliated Edward Hines, Jr. VA Hospital, which will give veterans diagnosed with mesothelioma access to his experience and the specialty care that is critical with a rare disease.
He also will return to Loyola’s highly touted thoracic transplant team, which made national news in 2014 when its staff performed five lung transplants in a 24-hour period. It was a herculean effort rarely duplicated anywhere in the world.
“One of my goals is to not just provide the best possible surgical care here, but to provide very patient-tailored, individualized care for this disease,” he said. “I won’t be boxed into one type of treatment. Every case is different and every one should be treated that way. This is about expanding horizons with a broader clinical base. The support system here is just outstanding.”
Vigneswaran said that although advances were made in the last decade with mesothelioma care, he expects even more progress in the next 10 years, much of it coming through more precise therapies, including immunotherapy and gene therapy.
“We can look at this disease now with a fresh eye, more hope than we ever thought possible before,” he said. “Patients are recovering faster, living longer with a good quality of life. Yes, there is hope on the horizon.”